ADORA1 and Arrhythmia: In the analysis of PPI and component-disease-target network pharmacology results, we found that the ADORA1 protein may be the main target in the PRP-based treatment of arrhythmia and that it participates in multiple signalling pathways, such as the cGMP-PKG, cAMP, and cardiac muscle contraction pathways.